Clinical Trials on Age Related Macular Degeneration in New Zealand

Total 792 results

Pfenex, Inc

Completed

Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration

Age Related Macular Degeneration (AMD)

New Zealand
Manhattan Eye, Ear & Throat Hospital
Alcon Research

Completed

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Maculopathy, Age-Related

United States
Apellis Pharmaceuticals, Inc.

Completed

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD (ASAP II)

Neovascular Age-Related Macular Degeneration

United States, Australia
Vitreous -Retina- Macula Consultants of New York

Unknown

Intense Treatment Regimen With Intravitreal Aflibercept Injection (I-TRAP)

Neovascular Age-Related Macular Degeneration

United States
The New York Eye & Ear Infirmary
iHealthScreen Inc

Recruiting

Telemedicine in Age-Related Macular Degeneration

Age Related Macular Degeneration

United States
Sandoz

Completed

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

Neovascular Age-related Macular Degeneration (nAMD)

United States
Notal Vision Inc.

Active, not recruiting

ForeseeHome NRich Registry

Age-Related Macular Degeneration

United States
Icahn School of Medicine at Mount Sinai
University of California, Los Angeles; National Eye Institute (NEI)

Recruiting

Snapshot Camera for AMD

Age Related Macular Degeneration

United States
Ophthotech Corporation

Completed

ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Ophthotech Corporation

Completed

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Weill Medical College of Cornell University

Completed

High-Resolution Ultrasound Imaging of the Retina and Choroid for Detection on Age Related Macular Degeneration

Age Related Macular Degeneration

United States
Benobio Co., Ltd.

Not yet recruiting

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

Australia
Weill Medical College of Cornell University
Riverside Research Institute

Unknown

Ultrasonic Evaluation of Ocular Tissues

Glaucoma | Age-Related Macular Degeneration | Tumors

United States
Sandoz

Completed

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

Neovascular Age-related Macular Degeneration (nAMD)

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

Age-related Macular Degeneration (AMD)

United States
The New York Eye & Ear Infirmary

Suspended

Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration

Dry Age Related Macular Degeneration

United States
LumiThera, Inc.

Completed

Study of Photobiomodulation Effect on Electroretinogram Outcomes in Dry Age-Related Macular Degeneration (ELECTROLIGHT)

Age Related Macular Degeneration

United States
Notal Vision Ltd.

Completed

Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment (AMD)

Age-Related Macular Degeneration

United States
Manhattan Eye, Ear & Throat Hospital
Alcon Research

Completed

Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.

Age-Related Macular Degenerations. | Subfoveal Neovascularization.

United States
Regeneron Pharmaceuticals

Completed

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)

Neovascular Age-Related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up

Neovascular Age-related Macular Degeneration

United States
Perceive Biotherapeutics, Inc.

Recruiting

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

Australia, Israel
ONL Therapeutics

Completed

ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

Geographic Atrophy

New Zealand, Australia
Novartis Pharmaceuticals

Completed

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Neovascular (Wet) Age-related Macular Degeneration

United States
Ohr Pharmaceutical Inc.

Withdrawn

Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Jeffrey S Heier
Regeneron Pharmaceuticals

Unknown

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD (PRO-CON)

Age-Related Macular Degeneration

United States
Regeneron Pharmaceuticals

Terminated

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA)

Neovascular Age-Related Macular Degeneration

United States, Japan
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Completed

A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study) (LAST)

Age Related Macular Degeneration

United States
Graybug Vision

Completed

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Ohr Pharmaceutical Inc.

Completed

Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

Neovascular Age Related Macular Degeneration

United States
Olix Pharmaceuticals, Inc.
Trial Runners, LLC

Recruiting

Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

United States
Kyowa Kirin, Inc.

Recruiting

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)

United States, Japan, Korea, Republic of, Australia
Hoffmann-La Roche

Recruiting

Extension Study for the Port Delivery System With Ranibizumab (Portal) (Portal)

Neovascular Age-Related Macular Degeneration

Belgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
Chengdu Origen Biotechnology Co., Ltd.

Recruiting

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Hoffmann-La Roche

Completed

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)

Neovascular Age-Related Macular Degeneration

United States
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Withdrawn

Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration (SEIRA)

Age Related Macular Degeneration | CNV | AMD

United States
LumiThera, Inc.
National Eye Institute (NEI)

Recruiting

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)

Dry Age-related Macular Degeneration

United States
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)

Age-Related Macular Degeneration

United States, Puerto Rico
LumiThera, Inc.

Active, not recruiting

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

Dry Age-related Macular Degeneration

United States
OcuTerra Therapeutics, Inc.

Completed

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration

United States
Manhattan Eye, Ear & Throat Hospital
QLT Inc.; Novartis

Completed

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States, Canada
PanOptica, Inc.

Completed

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

Age-Related Macular Degeneration (AMD)

United States
Lupin Ltd.

Recruiting

Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD

Neovascular Age-related Macular Degeneration

India
Ionis Pharmaceuticals, Inc.

Withdrawn

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Geographic Atrophy | Age Related Macular Degeneration

Australia, United States, New Zealand
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

Neovascular Age-related Macular Degeneration

United States, Puerto Rico
Genentech, Inc.

Completed

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) (HARBOR)

Age-related Macular Degeneration

United States

3

Subscribe